S-1/A: Biofrontera Ameluz Rights Acquisition & Resale Offering

Biofrontera Inc. announces the acquisition of full U.S. rights to its key product Ameluz and a significant common stock resale offering by selling stockholders, while facing ongoing financial challenges and potential dilution.

Summary

• Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatological conditions, primarily with its photodynamic therapy (PDT) product, Ameluz, and the RhodoLED lamp series.
• The company recently entered into an agreement on June 30, 2025, to acquire all U.S. rights to Ameluz and RhodoLED and associated patents from Biofrontera AG and its subsidiaries. This replaces a transfer pricing model with a royalty of 12% for U.S. Ameluz revenue below $65 million and 15% for revenue exceeding that threshold.
• This filing relates to the offering and resale of 13,602,176 shares of common stock by selling stockholders, issued upon conversion of Series C Convertible Preferred Stock, from which the company will not receive any proceeds.
• The company's second licensed product, Xepi, a topical antibiotic for impetigo, is facing manufacturing delays and the company decided in Q3 2024 to divest this product line, with a transaction anticipated to close in the second half of 2025.
• Ameluz PDT is used for actinic keratoses (AK), a pre-cancerous skin lesion, and holds approximately 2% of the estimated $4 billion total AK market, targeting an 11% share ($500 million) by converting cryotherapy treatments.
• Key product enhancements include the FDA approval of the larger RhodoLED XL lamp in late October 2021 and an increased maximally approved dosage of Ameluz from one to three tubes per treatment in October 2024.
• Clinical trials for Ameluz are ongoing for superficial basal cell carcinoma (last-patient-out completed Dec 2024), moderate to severe acne (last-patient-out expected Q3 2025), and actinic keratosis on trunk & extremities (recruitment near completion, last-patient-out expected Q1 2026). New trials for combination daylight PDT and squamous cell carcinoma in situ are planned for 2026.
• The company has a history of operating losses and anticipates continued losses, with substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 6

Explanation: The filing presents a mixed bag. Strategic positives like the acquisition of Ameluz rights, reduced royalty, increased dosage approval, and pipeline expansion are significant. However, these are heavily counterbalanced by severe financial risks, including a 'substantial doubt about our ability to continue as a going concern,' a history of operating losses, anticipated future losses, and substantial potential dilution from various convertible securities and warrants. The fact that the company receives no proceeds from this specific resale offering further dampens immediate financial benefit. The strategic moves are positive, but the underlying financial health and dilution risks are concerning.

Positives

• Acquisition of full U.S. rights to Ameluz and RhodoLED from Biofrontera AG, transitioning from a transfer price model (25-35%) to a lower royalty structure (12-15%), which is expected to finance R&D and support commercial growth.
• Gained direct control of all Ameluz clinical trials in the US as of June 1, 2024, allowing for more effective cost management and oversight.
• FDA approval in October 2024 to increase the maximally approved dosage of Ameluz from one to three tubes per treatment, offering greater flexibility and efficiency for healthcare professionals.
• Launch of the new, larger RhodoLED XL lamp in Q2 2024, enabling illumination of larger treatment areas.
• Development of a new Ameluz formulation (propylene glycol-free) to be implemented in 2024, with a patent application filed potentially extending protection to 2043.
• Ongoing clinical trials for Ameluz in new indications (superficial basal cell carcinoma, moderate to severe acne, AK on trunk & extremities) and planned trials for combination PDT and squamous cell carcinoma in situ, indicating pipeline expansion.
• Ameluz PDT therapy is highly effective with up to 91% clearance after one or two treatments and limited or no scarring.

Negatives

• The company will not receive any proceeds from the sale of 13,602,176 shares of common stock by the Selling Stockholders, limiting direct capital infusion from this specific offering.
• Substantial doubt about the company's ability to continue as a going concern.
• History of operating losses and anticipation of continued losses, with no assurance of future profitability.
• Sole source of revenue is from licensed products, making the business highly dependent on these agreements and their terms.
• Certain important patents for Ameluz expired in 2019, raising the risk of generic competition, which could significantly reduce Ameluz price and market share.
• Manufacturing delays have impacted revenue from the Xepi product line, leading to a decision to divest it.
• Significant potential for future dilution from the conversion of various preferred stocks (Series B, Series C, Series D), convertible notes, and exercise of warrants and stock options, totaling over 40 million additional shares beyond current outstanding common stock.
• Reliance on single or few contract manufacturers for Ameluz and RhodoLED lamps poses supply chain risks.
• Lack of control over some critical functions like sourcing, manufacturing, and regulatory approvals for licensed products (though control over Ameluz clinical trials has shifted).
• Risk of delisting from Nasdaq if compliance with listing standards is not maintained.
• The company has never paid dividends and does not intend to in the foreseeable future, meaning investor gains depend solely on stock price appreciation.

Risks

• Failure to comply with obligations under license agreements or termination of agreements could lead to loss of important license rights.
• Entry of generic versions of Ameluz following patent expiration in 2019 could lead to significant price reductions and market share loss.
• Business substantially depends on the success of Ameluz; failure to obtain/maintain regulatory approvals or reimbursement for existing/additional indications would be materially harmful.
• Reliance on single/few unaffiliated contract manufacturers for Ameluz and RhodoLED lamps; failure to maintain relationships or production could harm business.
• Licensors' or manufacturing partners' failure to produce products in sufficient quantities, at acceptable quality/cost, or comply with cGMP could delay commercialization or prevent meeting market demand.
• Involvement in lawsuits to defend or enforce patents related to licensed products, which could be expensive, time-consuming, and unsuccessful.
• Lack of control over sourcing, manufacture, and regulatory approvals of licensed products by existing/future collaborators could adversely affect strategy implementation.
• Inability to effectuate a timely sale of Xepi or receive consideration in excess of its carrying value.
• Limited or unavailable insurance coverage and medical expense reimbursement in certain market segments for licensed products.
• Healthcare legislative changes may have a material adverse effect on business and results of operations.
• Significant competition from other pharmaceutical and medical device companies, including existing treatments like cryotherapy.
• Uncertainty of research and development efforts; no assurance they will enhance commercial success.
• Substantial doubt about ability to continue as a going concern.
• History of operating losses and anticipated future losses; may never sustain profitability.
• Failure to obtain additional financing to support marketing or commercialization.
• Failure to maintain an effective system of internal controls could impair financial reporting and investor confidence.
• Failure to maintain compliance with Nasdaq listing standards could lead to delisting.
• Delay or termination of planned clinical trials for Ameluz expansion would result in unplanned expenses and adversely impact prospects and revenues.
• Dilution to stockholders from exercise/conversion of warrants, Series B Preferred, Series C Preferred, and convertible notes.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution and stock price decline.
• Charter documents and Delaware law could prevent a takeover considered favorable by stockholders and reduce stock price.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum.
• Warrants accounted for as a liability, with fair value changes reported in earnings, may adversely affect common stock market price.

Future Outlook

The company aims to expand Ameluz sales in the U.S., positioning it as the standard of care for actinic keratosis by acquiring new customers and growing the existing customer base. It plans to leverage future approvals and label extensions for its licensed products, particularly Ameluz, by furthering clinical development after taking over responsibility for U.S. clinical trials. The strategy also includes opportunistically adding complementary products or services through IP acquisition or licensing, and managing the existing portfolio, including the anticipated divestiture of the Xepi product line in the second half of 2025. Clinical trial results for Ameluz in superficial basal cell carcinoma are expected in Q2 2025, and for moderate to severe acne and AK on trunk & extremities in Q3 2026. New trials for combination daylight PDT and squamous cell carcinoma in situ are planned for 2026.

Management Comments

• Our goal is to improve the effectiveness of our commercial team by allowing sales representatives to carry approved devices with them allowing for easier product demonstrations and evaluations.
• We believe that [the new contract manufacturer for Xepi] will be able to supply enough of the Xepi product line to meet market demand for as long as we maintain it.
• By executing these three strategic objectives, we will fuel company growth, deepen our trusted relationships in the dermatology community, and above all, help patients live healthier, more fulfilling lives.

Industry Context

The company operates in the biopharmaceutical market, specifically targeting dermatological conditions with a focus on photodynamic therapy (PDT) for pre-cancerous skin lesions (actinic keratoses) and topical antibiotics for bacterial skin infections (impetigo). The AK market is estimated at $4 billion, with PDT currently holding a small 2% share, dominated by traditional treatments like cryotherapy (86%) and topical medications (12%). The company's strategy to expand Ameluz's market share by targeting the larger cryotherapy segment for multiple lesions positions it to disrupt established treatment paradigms. The divestiture of Xepi indicates a strategic focus on the core PDT business, streamlining the portfolio in a competitive pharmaceutical landscape.

Comparison to Industry Standards

• Ameluz PDT's reported efficacy of up to 91% clearance after one or two treatments with limited or no scarring compares favorably to cryotherapy, which is estimated to be approximately 86% of the market but may not be as effective and may leave scarring.
• The company's targeted market of $500 million (11% of the total AK market) by converting cryotherapy treatments for more than 14 lesions suggests a strategic focus on a specific, underserved segment where PDT may offer superior outcomes compared to the current standard of care.
• The primary competitor in the PDT space, Levulan and its associated light Blu-U, is not detailed enough in the filing to provide a specific comparative analysis of their results or market share beyond the general PDT market share.
• The company's decision to divest Xepi due to manufacturing delays and limited revenue, while Ferrer is qualifying a new manufacturer, highlights challenges in the competitive topical antibiotic market where consistent supply is crucial.

Corporate Governance

Legal Proceedings

• The Biofrontera Group (a related party) has been involved in lawsuits to defend or enforce patents related to licensed products and they or another licensor may become involved in similar suits in the future, which could be expensive, time-consuming and unsuccessful.
• The company may become involved in litigation, including intellectual property infringement lawsuits related to its licensed products.

Related Party Transactions

• Acquisition of all U.S. rights to Ameluz and RhodoLED and associated patents from Biofrontera AG and certain of its subsidiaries (a related party, as Biofrontera AG holds approximately 3.7% of common stock). This involves a new royalty structure (12-15% of U.S. Ameluz revenue) and the issuance of 3,019 shares of Series D Convertible Preferred Stock to Biofrontera AG.
• The Ameluz LSA and its amendments are with Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH (Ameluz Licensors), which are part of the Biofrontera Group.
• Biofrontera AG holds approximately 3.7% of the outstanding shares of common stock as of August 13, 2025.
• The company's wholly owned subsidiary Biofrontera Discovery GmbH and German presence Bio-FRI facilitate relationships with the Ameluz Licensor.

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the large number of shares offered for resale by selling stockholders and the potential conversion of various preferred stocks, convertible notes, and warrants. The company will not receive proceeds from this resale, limiting direct capital infusion. Share price volatility is a risk. Anti-takeover provisions may limit shareholder influence.
• Employees: Continued R&D activities and commercial growth trajectory for Ameluz could provide job stability and growth opportunities. Equity incentive plans are in place.
• Customers (Healthcare Providers/Patients): Increased dosage flexibility for Ameluz and the larger RhodoLED XL lamp aim to improve convenience and treatment efficiency. Ongoing clinical trials for new indications could expand treatment options.
• Suppliers/Creditors: The 'going concern' doubt and need for additional financing could pose risks to creditors. Manufacturing delays for Xepi highlight supply chain vulnerabilities.
• Licensors (Biofrontera AG, Ferrer): The acquisition of Ameluz rights and the new royalty structure define a new financial relationship with Biofrontera AG. The planned divestiture of Xepi impacts the relationship with Ferrer.

Next Steps

• Selling Stockholders may sell all or a portion of the shares of common stock from time to time.
• Anticipated closing of Xepi divestiture transaction during the second half of 2025.
• Clinical Study Report (CSR) for Ameluz superficial basal cell carcinoma trial expected Q2 2025.
• Last-patient-out of treatment phase for Ameluz moderate to severe acne trial expected Q3 2025.
• CSR for Ameluz moderate to severe acne trial expected Q3 2026.
• Last-patient-out of treatment phase for Ameluz actinic keratosis (trunk & extremities) trial expected Q1 2026.
• CSR for Ameluz actinic keratosis (trunk & extremities) trial expected Q3 2026.
• Plan to start enrollment for Ameluz combination daylight and conventional PDT trial in 2026.
• Plan to start enrollment for Ameluz squamous cell carcinoma in situ trial in 2026.
• New Ameluz formulation (propylene glycol-free) to be implemented in all US productions starting in 2024.
• Stockholder approval required for the issuance of shares upon conversion of Series D Preferred Stock and for certain Series B Preferred Stock conversions under Nasdaq listing rules.

Key Dates

Recommendation

The company is undergoing a significant strategic shift by acquiring full U.S. rights to its core product, Ameluz, and streamlining its portfolio by divesting Xepi. These moves, coupled with recent FDA approvals for Ameluz and ongoing clinical trials, suggest a focused effort to drive future growth and profitability in its primary market. However, the immediate financial outlook is challenging, with a history of operating losses, anticipated continued losses, and a 'going concern' warning. The substantial potential for dilution from various convertible securities and warrants, combined with the fact that the company receives no proceeds from this specific resale offering, creates significant downside risk for current shareholders. A 'hold' recommendation reflects the balance between the long-term strategic potential of the Ameluz franchise and the immediate financial uncertainties and dilution pressures. Investors should monitor the company's progress in clinical trials, market penetration of Ameluz, and its ability to secure additional financing and address its going concern issues.

Keywords

Biopharmaceutical, Dermatology, Photodynamic Therapy, Ameluz, Actinic Keratosis, RhodoLED, SEC Filing, S-1/A, Stock Resale, Preferred Stock, Clinical Trials, Xepi, Impetigo, Going Concern, Dilution, Nasdaq